Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic Diseases

Archive ouverte

Rossi, Michele | Martinengo, Bianca | Diamanti, Eleonora | Salerno, Alessandra | Rizzardi, Nicola | Fato, Romana | Bergamini, Christian | Souza de Oliveira, Andressa | de Araújo Marques Ferreira, Thais | Andrade Holanda, Cleonice | Romeiro, Luiz, Antonio Soares | Soeiro, Maria, de Nazaré Correia | Nunes, Krislayne | Ferreira de Almeida Fiuza, Ludmila | Meuser Batista, Marcos | Fraga, Carlos, a M | E. A. Alkhalaf, Hamed | Elmahallawy, Ehab, Kotb | Ebiloma, Godwin, U | de Koning, Harry, P | Vittorio, Serena | Vistoli, Giulio | Blanquart, Christophe | Bertrand, Philippe | Bolognesi, Maria, Laura

Edité par CCSD ; American Chemical Society -

International audience. The search for new drugs fulfilling One Health and Green Chemistry requirements is an urgent call. Here, for the first time, we envisaged developing SAHA analogues by starting from the cashew nutshell liquid (CNSL) agro-industrial waste and employing a metathesis approach. This sustainable combination (comprising principles #7 and #9) allowed a straightforward synthesis of compounds 13-20. All of them were found to not be toxic on HepG2, IMR-32, and L929 cell lines. Then, their potential against major human and animal VBPDs was assessed. Compound 13 emerged as a green hit against the trypomastigote forms of T. b. brucei. In silico studies showed that the T. b. brucei HDAC (TbDAC) catalytic pocket could be occupied in a similar binding mode by both SAHA and 13, providing a putative explanation for its antiparasitic activity mechanism of action (13, EC 50 = 0.7 ± 0.2 μM).

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion